Publications





Rectal Cancer, Version 2.2015.
J Natl Compr Canc Netw 2015 Jun;13(6):719-28; quiz 728
Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; UC San Diego Moores Cancer Center; Roswell Park Cancer Institute; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Memorial Sloan Kettering Cancer Center; Huntsman Cancer Institute at the University of Utah; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.













Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
BMC Cancer 2005 Sep 16;5:116. Epub 2005 Sep 16.
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
Oncol Rep 2005 Jun;13(6):1145-52
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute-Navy, National Naval Medical Center, Bethesda, MD 20889-5105, USA.


A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Cancer Chemother Pharmacol 2003 Dec 29;52(6):487-96. Epub 2003 Aug 29.
National Cancer Institute-Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889, USA.

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.
Cancer Chemother Pharmacol 2003 Oct 18;52(4):333-8. Epub 2003 Jun 18.
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA.


Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Cancer Chemother Pharmacol 2003 Jul 18;52(1):79-85. Epub 2003 Apr 18.
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, MD 20889-5105, USA.



Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Clin Cancer Res 2002 May;8(5):1045-50
National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA.

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.
Evid Based Complement Alternat Med 2013 27;2013:964592. Epub 2013 Oct 27.
The Cancer Team at Bellin Health, 1580 Commanche Avenue, Green Bay, WI 54313, USA ; National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, USA.



OF